Overview

Dexmedetomidine vs Fentanyl for BMT

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
A randomized controlled clinical trial to examine effects of intranasal dexmedetomidine, an α2-adrenorecptor agonist, on pain control and agitation in children undergoing BMT.
Phase:
Phase 4
Details
Lead Sponsor:
Children's National Research Institute
Children's Research Institute
Collaborators:
Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer
Treatments:
Dexmedetomidine
Fentanyl